In a large cohort of patients with HER2-positive early breast cancer (n=396), a dual HER2-targeted combination of pertuzumab and trastuzumab, together with 8 cycles of taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, was well tolerated and achieved high rates of pathological complete response.
http://annonc.oxfordjournals.org/cgi/content/short/mdw610v1?rss=1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου